Limits...
Genetic polymorphisms in ERCC1 and ERCC2 genes are associated with response to chemotherapy in osteosarcoma patients among Chinese population: a meta-analysis

View Article: PubMed Central - PubMed

ABSTRACT

Background: There existed controversies about the association between the response to chemotherapy for osteosarcoma (OS) patients and the genetic polymorphisms in excision repair cross-complementation group (ERCC1 and ERCC2) genes. We aimed to perform a meta-analysis to comprehensively evaluate the association.

Method: We searched multiple databases for literature retrieval including the PubMED (1966 ∼ 2017), Embase (1980 ∼ 2017), and the Web of science (1945 ∼ 2017). The overall odds ratios(OR) and their corresponding 95% confidence interval (CI) were calculated for the three polymorphisms under the dominant, recessive, and allelic models.

Results: From six eligible articles in our study, we found that for ERCC1 rs11615 polymorphism, a significant association was detected between the chemotherapy response and the polymorphism under all three models (dominant model: OR = 2.015, P = 0.005; recessive model: OR = 1.791, P = 0.003; allelic model: OR = 1.677, P = 0.003), and OS patients carrying C allele in rs11615 polymorphism were more likely to response to chemotherapy. In terms of ERCC2 rs1799793 polymorphism, this polymorphism was significantly associated with the response to chemotherapy for OS patients under recessive model (OR = 1.337, P = 0.036), and patients with AG + AA genotype in rs1799793 polymorphism were more appropriate to receive chemotherapy. With respect to ERCC2 rs13181 polymorphism, this polymorphism was not correlated with the response to chemotherapy for OS patients under all three models.

Conclusions: Our meta-analysis suggested that among Chinese population, the rs11615 and rs1799793 polymorphisms were significantly correlated with the response to chemotherapy for patients with OS, and patients with CC or TC + CC genotypes in ERCC1 rs11615 polymorphism or AG + AA genotype in ERCC2 rs1799793 polymorphism were more suitable for chemotherapy.

No MeSH data available.


Flow diagram displaying study selection and specific reasons for exclusion from the mete-analysis
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC5383995&req=5

Fig1: Flow diagram displaying study selection and specific reasons for exclusion from the mete-analysis

Mentions: Based on our search strategy, we retrieved 56 literatures from PUBMED, 86 from Embase, and 43 from the Web of science. Twenty-five duplicated articles were removed, leaving 130 literatures for further assessment. After screening the titles, 54 literatures were eliminated. Then the remaining 76 articles were estimated for eligibility according to our inclusion and exclusion criteria. Finally six eligible articles [12–14, 17, 20, 21] were included in our meta-analysis. The flow diagram of study selection process and reasons for exclusion was represented in Fig. 1. Table 1 gives a summary of the characteristics of each included study.Fig. 1


Genetic polymorphisms in ERCC1 and ERCC2 genes are associated with response to chemotherapy in osteosarcoma patients among Chinese population: a meta-analysis
Flow diagram displaying study selection and specific reasons for exclusion from the mete-analysis
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC5383995&req=5

Fig1: Flow diagram displaying study selection and specific reasons for exclusion from the mete-analysis
Mentions: Based on our search strategy, we retrieved 56 literatures from PUBMED, 86 from Embase, and 43 from the Web of science. Twenty-five duplicated articles were removed, leaving 130 literatures for further assessment. After screening the titles, 54 literatures were eliminated. Then the remaining 76 articles were estimated for eligibility according to our inclusion and exclusion criteria. Finally six eligible articles [12–14, 17, 20, 21] were included in our meta-analysis. The flow diagram of study selection process and reasons for exclusion was represented in Fig. 1. Table 1 gives a summary of the characteristics of each included study.Fig. 1

View Article: PubMed Central - PubMed

ABSTRACT

Background: There existed controversies about the association between the response to chemotherapy for osteosarcoma (OS) patients and the genetic polymorphisms in excision repair cross-complementation group (ERCC1 and ERCC2) genes. We aimed to perform a meta-analysis to comprehensively evaluate the association.

Method: We searched multiple databases for literature retrieval including the PubMED (1966 ∼ 2017), Embase (1980 ∼ 2017), and the Web of science (1945 ∼ 2017). The overall odds ratios(OR) and their corresponding 95% confidence interval (CI) were calculated for the three polymorphisms under the dominant, recessive, and allelic models.

Results: From six eligible articles in our study, we found that for ERCC1 rs11615 polymorphism, a significant association was detected between the chemotherapy response and the polymorphism under all three models (dominant model: OR = 2.015, P = 0.005; recessive model: OR = 1.791, P = 0.003; allelic model: OR = 1.677, P = 0.003), and OS patients carrying C allele in rs11615 polymorphism were more likely to response to chemotherapy. In terms of ERCC2 rs1799793 polymorphism, this polymorphism was significantly associated with the response to chemotherapy for OS patients under recessive model (OR = 1.337, P = 0.036), and patients with AG + AA genotype in rs1799793 polymorphism were more appropriate to receive chemotherapy. With respect to ERCC2 rs13181 polymorphism, this polymorphism was not correlated with the response to chemotherapy for OS patients under all three models.

Conclusions: Our meta-analysis suggested that among Chinese population, the rs11615 and rs1799793 polymorphisms were significantly correlated with the response to chemotherapy for patients with OS, and patients with CC or TC + CC genotypes in ERCC1 rs11615 polymorphism or AG + AA genotype in ERCC2 rs1799793 polymorphism were more suitable for chemotherapy.

No MeSH data available.